Welcome to our dedicated page for Genmab A/S SEC filings (Ticker: GNMSF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Genmab A/S (GNMSF) SEC filings page on Stock Titan provides access to U.S. regulatory documents filed by this Denmark-based foreign issuer. Genmab A/S furnishes current reports on Form 6-K under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 and indicates that it files annual reports under cover of Form 20-F or Form 40-F.
One highlighted filing is a Form 6-K for the month of September 2025, dated September 23, 2025. In that document, Genmab A/S states that the report is deemed incorporated by reference into several of its Form S-8 registration statements. This shows how its current reports are linked to securities registered for employee or related benefit plans.
The exhibit index for that Form 6-K lists a Company Announcement: Major Shareholder Announcement and a Standard form for notification of major holdings. These exhibits illustrate the type of ownership and major-holdings information that can be found in the company’s SEC submissions and are particularly relevant for users interested in changes in significant shareholdings.
On Stock Titan, users can review Genmab A/S filings such as Form 6-K and related exhibits, with AI-powered tools that summarize key points and clarify how filings relate to registration statements like Form S-8. Real-time updates from EDGAR and structured access to these documents help users analyze GNMSF’s regulatory history and shareholder-related disclosures more efficiently.
Genmab A/S reported that worldwide 2025 net trade sales of the cancer medicine DARZALEX (daratumumab), including the subcutaneous DARZALEX FASPRO formulation, were USD 14,351 million as reported by Johnson & Johnson. Net trade sales were USD 8,266 million in the U.S. and USD 6,085 million in the rest of the world. Genmab receives royalties on all worldwide net sales of both the intravenous and subcutaneous products under its exclusive license agreement with Johnson & Johnson. The filing also reiterates that Genmab is a biotechnology company focused on antibody-based medicines, with multiple approved therapies and a late-stage clinical pipeline.
Genmab A/S has furnished a Form 6-K for September 2025 that attaches two exhibits related to a major shareholder. The exhibits are a company announcement dated September 23, 2025 and a standard notification of major holdings. The filing is incorporated by reference into Genmab’s existing Form S-8 registration statements.